Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Stanford University |
---|---|
Information provided by: | Stanford University |
ClinicalTrials.gov Identifier: | NCT00349830 |
The purpose of this trial is to collect blood serum from cancer patients with tumors at different disease sites (such as pancreas, head and neck, and breast) prior to and at subsequent points following anti-cancer therapy to discover novel serum markers of response.
Condition | Intervention |
---|---|
Carcinomas (Including Squamous Cell and Adenocarcinoma) |
Procedure: blood draw |
Study Type: | Interventional |
Study Design: | Diagnostic, Non-Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy |
Estimated Enrollment: | 300 |
Study Start Date: | January 2002 |
Estimated Primary Completion Date: | January 2022 (Final data collection date for primary outcome measure) |
This is a blood serum collection study at Stanford University for patients with cancer at a variety of disease sites. The purpose of this study is to collect and store blood serum from patients before, during, and after anti-cancer therapy to find new biomarkers that signal disease or response to anti-cancer therapy. The collection and analysis of these biomarkers may lead to improved diagnostic and treatment therapies for certain cancers in the future. We are also interested in collecting blood serum from healthy individuals such as the spouses, relatives, and friends of cancer patients to obtain healthy controls for comparison
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:- Over age 18, no maximum age limit
Exclusion Criteria:- Less than 18 years old
Contact: Jeff Kim | (650) 498-7703 | jeff.kim@stanford.edu |
United States, California | |
Stanford University School of Medicine | Recruiting |
Stanford, California, United States, 94305 | |
Contact: Jeff Kim 650-498-7703 jeff.kim@stanford.edu | |
Contact: Cancer Clinical Trials Office (650) 498-7061 | |
Principal Investigator: Albert Koong | |
Sub-Investigator: Anson W Lowe | |
Sub-Investigator: Quynh-Thu Le | |
Sub-Investigator: James M Ford | |
Sub-Investigator: George Albert Fisher M.D. Ph.D. |
Principal Investigator: | Albert Koong | Stanford University |
Responsible Party: | Stanford University School of Medicine ( Albert Koong, Principal Investigator ) |
Study ID Numbers: | VAR0006, 77923, NCT00349830, VAR0006 |
Study First Received: | July 5, 2006 |
Last Updated: | May 8, 2009 |
ClinicalTrials.gov Identifier: | NCT00349830 History of Changes |
Health Authority: | United States: Institutional Review Board |
Adenocarcinoma Neoplasms, Glandular and Epithelial Carcinoma |
Neoplasms Neoplasms by Histologic Type Adenocarcinoma Neoplasms, Glandular and Epithelial Carcinoma |